ENLIVEX THERAPEUTICS LTD's ticker is ENLV and the CUSIP is M4130Y106. A total of 25 filers reported holding ENLIVEX THERAPEUTICS LTD in Q3 2021. The put-call ratio across all filers is 0.85 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,090 | -97.7% | 690 | -96.1% | 0.00% | – |
| Q2 2023 | $46,787 | -59.1% | 17,810 | -43.4% | 0.00% | – |
| Q1 2023 | $114,489 | -13.1% | 31,453 | -6.0% | 0.00% | – |
| Q4 2022 | $131,774 | -3.1% | 33,445 | +4.9% | 0.00% | – |
| Q3 2022 | $136,000 | +63.9% | 31,871 | +73.4% | 0.00% | – |
| Q2 2022 | $83,000 | -16.2% | 18,381 | +3.9% | 0.00% | – |
| Q1 2022 | $99,000 | -26.7% | 17,683 | -18.3% | 0.00% | – |
| Q4 2021 | $135,000 | -11.2% | 21,646 | +40.1% | 0.00% | – |
| Q3 2021 | $152,000 | +26.7% | 15,454 | +15.2% | 0.00% | – |
| Q2 2021 | $120,000 | 0.0% | 13,420 | +23.4% | 0.00% | – |
| Q1 2021 | $120,000 | -36.5% | 10,872 | -51.5% | 0.00% | – |
| Q4 2020 | $189,000 | +209.8% | 22,399 | +119.0% | 0.00% | – |
| Q3 2020 | $61,000 | +2950.0% | 10,230 | +2873.8% | 0.00% | – |
| Q2 2020 | $2,000 | -91.7% | 344 | -88.0% | 0.00% | – |
| Q4 2019 | $24,000 | -71.8% | 2,873 | -9.7% | 0.00% | – |
| Q3 2019 | $85,000 | +157.6% | 3,181 | +106.6% | 0.00% | – |
| Q2 2019 | $33,000 | – | 1,540 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACT CAPITAL MANAGEMENT, LLC | 15,000 | $68,000 | 0.10% |
| Susquehanna International Group Ltd. | 22,002 | $98,000 | 0.02% |
| ARK Investment Management | 331,001 | $1,658,000 | 0.01% |
| Compagnie Lombard Odier SCmA | 50,000 | $223,000 | 0.01% |
| EDMOND DE ROTHSCHILD HOLDING S.A. | 13,000 | $59,000 | 0.00% |
| OSAIC HOLDINGS, INC. | 400 | $2,000 | 0.00% |
| BANK OF AMERICA CORP /DE/ | 1,215 | $5,000 | 0.00% |
| WELLS FARGO & COMPANY/MN | 12,373 | $56,000 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| GROUP ONE TRADING, L.P. | 2,884 | $13,000 | 0.00% |